Evidence map›Paper›PMID 34603639›Full record

ArticleRare tumors2021

Hypofractionated radiation in secretory breast cancer: A case report.

Ken Tatebe, Claudia Perez, Lydia Usha, Ritu Ghai, Dian Wang, Parul Barry

Open access · goldAbstract readCase Reports
In one paragraph

Article in Rare tumors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ken TatebeDepartment of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA.
Claudia PerezDepartment of Surgery, Rush University Medical Center, Chicago, IL, USA.
Lydia UshaDepartment of Medical Oncology, Rush University Medical Center, Chicago, IL, USA.
Ritu GhaiDepartment of Pathology, Advocate Healthcare, Oak Lawn, IL, USA.
Dian WangDepartment of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA.
Parul BarryHillman Cancer Center, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0002-9759-4671
Rush University Medical Center · USAdvocate Health Care · USMagee-Womens Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secretory carcinoma is a rare and indolent breast cancer with a lack of established treatment paradigms. We describe a case of a woman who underwent breast conservative therapy in the modern era. A 48 year old woman with a screen-detected left breast cancer was found to have early-stage secretory carcinoma after definitive breast conservation surgery. Further management with adjuvant radiation was recommended. After definitive breast conservative surgery, final pathology was notable for secretory breast carcinoma due to the immunohistologic characteristics of the tumor, ETV6-NTRK3 gene fusion, and histologic findings. After multi-disciplinary discussion, it was recommended that the patient proceed with adjuvant radiation. She was treated using a modestly hypofractionated regimen of 4256 cGy in 16 fractions. She tolerated the treatment well, developing only grade 1 radiation dermatitis. At 1 year follow-up she was clinically and radiographically free of disease. With a shift in management toward breast conservative therapy, defining the role of adjuvant radiation for secretory carcinomas in the modern era is of increasing importance. Modestly hypofractionated radiation is well-tolerated. Oncologic outcomes will be assessed with continued long-term follow-up.

Indexed as

Breast cancerbreast conservationhypofractionationradiationsecretory breast cancer

Identifiers

PMID34603639
PMCPMC8481704
OpenAlexW3203781404

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.